Mylan (MYL, $19.84) gets FDA nod on its generic version of anti-stroke drug

Mylan got an approval from the Food and Drug Administration on the  generic-drug maker's version of Eliquis.

Eliquis is a tablet for  reducing stroke risks and pulmonary embolisms in individuals. The generic, apixaban, is for patients with nonvalvular atrial fibrillation and those who have undergone hip or knee replacement surgery. It’s also used against deep vein thrombosis.

The approval is part of FDA’s program Drug Competition Action Plan, which is aimed at providing more affordable medicine for patients.

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.